UnitedHealth Makes Unsolicited Takeover Bid for Amedisys
By Colin Kellaher
Amedisys on Monday said it has received an unsolicited, $3.26 billion takeover proposal from a unit of UnitedHealth Group that could upend the healthcare-services provider's deal to be acquired by Option Care Health.
Amedisys said UnitedHealth's Optum health-services arm has proposed paying $100 a share in cash for Amedisys, a nearly 26% premium to Friday's closing price of $79.47 for the Baton Rouge, La., company, which in May said it would combine with Option Care in an all-stock deal.
Based on Friday's closing prices, the Option Care deal is currently worth about $2.8 billion, or $86.29 a share, to Amedisys investors.
Amedisys said its board has determined that the Optum proposal could reasonably be expected to result in an superior deal to the one with Option Care, and that it is currently in exploratory talks with Optum.
Trading in shares of Amedisys was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2023 08:51 ET (12:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024